Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions

<b>Background/Objectives:</b> Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer mortality globally, though advances in targeted therapies have improved treatment outcomes. The mesenchymal–epithelial transition (<i>MET</i>) gene plays a significant role in NSCLC, often through prot...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Kinsley Wang, Robert Hsu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2024-10-01
Edice:	Antibodies
Témata:	MET (mesenchymal–epithelial transition factor) NSCLC (non-small-cell lung cancer) EGFR-mutated NSCLC targeted therapies amivantamab
On-line přístup:	https://www.mdpi.com/2073-4468/13/4/88
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!